Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (221-230 of 394) with videos related to

Pageof 40
Sort By:
Annals of the Rheumatic Diseases|May 23, 2019
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studiesArthur Kavanaugh, Alice Gottlieb, Akimichi Morita, et al.
Journal of Medical Economics|May 3, 2018
Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severityMwangi J Murage, Amanda Anderson, Susan A Oliveria, et al.
Current Rheumatology Reports|September 22, 2020
Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMANStacie Bell, Joseph F Merola, Dan E Webster, et al.
The Journal of Rheumatology|April 2, 2022
Report of the Skin Research Working Groups from the GRAPPA 2021 Annual MeetingJenna E Yousif, Joseph F Merola, Lourdes M Perez-Chada, et al.
Journal of the American Academy of Dermatology|July 11, 2021
Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centersMichelle S Min, Abeer Alsarheed, Bina Kassamali, et al.
Frontiers in Medicine|February 13, 2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Frontiers in Medicine|March 28, 2023
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Clinical and Experimental Dermatology|May 11, 2024
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis RegistryCarly Grant, Lourdes M Perez-Chada, Ryan W Harrison, et al.
Journal of the American Academy of Dermatology|December 16, 2020
De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysisAi-Tram N Bui, Sean Singer, Jesse Hirner, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
Pageof 40

Showing results (221-230 of 394) with videos related to

Sort By:
Pageof 40
Annals of the Rheumatic Diseases|May 23, 2019
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studiesArthur Kavanaugh, Alice Gottlieb, Akimichi Morita, et al.
Journal of Medical Economics|May 3, 2018
Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severityMwangi J Murage, Amanda Anderson, Susan A Oliveria, et al.
Current Rheumatology Reports|September 22, 2020
Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMANStacie Bell, Joseph F Merola, Dan E Webster, et al.
The Journal of Rheumatology|April 2, 2022
Report of the Skin Research Working Groups from the GRAPPA 2021 Annual MeetingJenna E Yousif, Joseph F Merola, Lourdes M Perez-Chada, et al.
Journal of the American Academy of Dermatology|July 11, 2021
Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centersMichelle S Min, Abeer Alsarheed, Bina Kassamali, et al.
Frontiers in Medicine|February 13, 2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Frontiers in Medicine|March 28, 2023
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Clinical and Experimental Dermatology|May 11, 2024
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis RegistryCarly Grant, Lourdes M Perez-Chada, Ryan W Harrison, et al.
Journal of the American Academy of Dermatology|December 16, 2020
De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysisAi-Tram N Bui, Sean Singer, Jesse Hirner, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
Pageof 40